Tech Company Financing Transactions
Symbiomix Therapeutics Funding Round
On 6/30/2013, Symbiomix Therapeutics raised funding from F-Prime Capital.
Transaction Overview
Company Name
Announced On
6/30/2013
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
105 Lock St. 409
Newark, NJ 07103
USA
Newark, NJ 07103
USA
Phone
Website
Email Address
Not Recorded
Overview
Symbiomix Therapeutics is a biopharmaceutical company developing innovative medicines for serious women's health infections that have been long neglected and are in need of new therapeutic options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Klaus Veitinger
Chief Financial Officer
Robert Jacks
Chief Medical Officer
Carol Braun
Chief Scientific Officer
Helen Pentikis
VP - Operations
Nikki Adetoro
Browse more venture capital transactions:
Prev: 6/30/2013: 1Mind venture capital transaction
Next: 6/30/2013: Helical Solutions venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs